{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:08:11Z","timestamp":1784354891648,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Biohaven Pharmaceuticals, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Glutamate signaling activates MAPK and PI3K\/AKT pathways in tumor cells. Treatment with riluzole, a glutamate release inhibitor, has been previously shown to be safe in melanoma patients and produced biologic effects, but did not lead to radiographic responses, possibly due to poor pharmacokinetic properties. Therefore, we conducted a phase Ib trial to determine the safety and tolerability of the combination of the riluzole prodrug troriluzole (BHV-4157, trigriluzole) and the PD-1 antibody nivolumab in patients with advanced solid tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with advanced or refractory solid tumors and measurable disease per RECIST 1.1 were treated with increasing doses of troriluzole using a semi-Bayesian modified toxicity probability interval dose escalation procedure. Troriluzole monotherapy was orally self-administered for a 14-day lead-in period followed by continuation of troriluzole in combination with nivolumab 240\u00a0mg IV every 2\u00a0weeks. Endpoints included safety, pharmacokinetics (PK) and efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We enrolled 14 patients with advanced solid tumors (melanoma\u2009=\u20093, NSCLC\u2009=\u20093, renal cell carcinoma\u2009=\u20092, bladder\/urothelial\u2009=\u20092, ovarian cancer\u2009=\u20091, adenoid cystic carcinoma\u2009=\u20091, pleural mesothelial\u2009=\u20091, head and neck cancer\u2009=\u20091). Eleven patients had cancer progression on prior therapy with PD-1 or PD-L1 agent. Patients received troriluzole total daily doses from 140 to 560\u00a0mg (divided). The most common treatment-related adverse events (TRAE) occurring in\u2009\u2265\u20095 patients (&gt;\u200935%) were transaminitis and increased lipase. DLT (dose-limiting toxicity) occurred in 3 patients: (1) grade 3 anorexia, (2) grade 3 fatigue and, (3) grade 3 atrial fibrillation. Six patients were treated at the MTD (maximum tolerated dose). No subjects discontinued treatment due to AEs. One response occurred (7%), which was a partial response in a subject who had PD-1 refractory disease. The 6-month PFS rate was 21%. PK data showed that the prodrug troriluzole was efficiently cleaved into riluzole by 2-h post-dosing in all dose cohorts tested.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The combination of troriluzole and nivolumab was safe and well-tolerated. The MTD of troriluzole was determined to be 420\u00a0mg total daily dose. The observed antitumor activity, primarily disease stabilization, is of interest in patients with PD-1 resistant tumors.<\/jats:p>\n                <jats:p><jats:italic>Trial Registration<\/jats:italic> ClinicalTrials.gov Identifier NCT03229278.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-022-00732-w","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T04:02:43Z","timestamp":1656734563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors"],"prefix":"10.1186","volume":"27","author":[{"given":"Ann W.","family":"Silk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biren","family":"Saraiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Groisberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Girda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichung","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Palmeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracie","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Coric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Zloza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Vieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Mehnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"issue":"5","key":"732_CR1","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-06-3665","volume":"67","author":"J Namkoong","year":"2007","unstructured":"Namkoong J, Shin SS, Lee HJ, Mar\u00edn YE, Wall BA, Goydos JS, et al. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Cancer Res. 2007;67(5):2298\u2013305.","journal-title":"Cancer Res"},{"issue":"1","key":"732_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/ng1148","volume":"34","author":"PM Pollock","year":"2003","unstructured":"Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet. 2003;34(1):108\u201312.","journal-title":"Nat Genet"},{"issue":"9","key":"732_CR3","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1158\/1078-0432.CCR-04-1912","volume":"11","author":"HJ Chang","year":"2005","unstructured":"Chang HJ, Yoo BC, Lim SB, Jeong SY, Kim WH, Park JG. Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res. 2005;11(9):3288\u201395.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"732_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10549-011-1624-x","volume":"132","author":"CL Speyer","year":"2012","unstructured":"Speyer CL, Smith JS, Banda M, DeVries JA, Mekani T, Gorski DH. Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Res Treat. 2012;132(2):565\u201373.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"732_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.4161\/cbt.9.6.10898","volume":"9","author":"KS Brocke","year":"2010","unstructured":"Brocke KS, Staufner C, Luksch H, Geiger KD, Stepulak A, Marzahn J, et al. Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther. 2010;9(6):455\u201368.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"732_CR6","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1046\/j.1471-4159.2003.01633.x","volume":"84","author":"M D'Onofrio","year":"2003","unstructured":"D\u2019Onofrio M, Arcella A, Bruno V, Ngomba RT, Battaglia G, Lombari V, et al. Pharmacological blockade of mGlu2\/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem. 2003;84(6):1288\u201395.","journal-title":"J Neurochem"},{"issue":"3","key":"732_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1215\/S1152851704000961","volume":"7","author":"A Arcella","year":"2005","unstructured":"Arcella A, Carpinelli G, Battaglia G, D\u2019Onofrio M, Santoro F, Ngomba RT, et al. Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol. 2005;7(3):236\u201345.","journal-title":"Neuro Oncol"},{"issue":"10","key":"732_CR8","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1046\/j.1460-9568.2003.02657.x","volume":"17","author":"E Aronica","year":"2003","unstructured":"Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, Leenstra S, et al. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci. 2003;17(10):2106\u201318.","journal-title":"Eur J Neurosci"},{"issue":"4","key":"732_CR9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00418-009-0613-1","volume":"132","author":"A Stepulak","year":"2009","unstructured":"Stepulak A, Luksch H, Gebhardt C, Uckermann O, Marzahn J, Sifringer M, et al. Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol. 2009;132(4):435\u201345.","journal-title":"Histochem Cell Biol"},{"issue":"9","key":"732_CR10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G, Lacomblez L, Meininger V. A controlled trial of Riluzole in Amyotrophic lateral Sclerosis. N Engl J Med. 1994;330(9):585\u201391.","journal-title":"N Engl J Med"},{"issue":"3","key":"732_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S0306-4522(97)00604-0","volume":"85","author":"C Zona","year":"1998","unstructured":"Zona C, Siniscalchi A, Mercuri NB, Bernardi G. Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience. 1998;85(3):931\u20138.","journal-title":"Neuroscience"},{"issue":"11","key":"732_CR12","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-08-3303","volume":"15","author":"D Yip","year":"2009","unstructured":"Yip D, Le MN, Chan JL, Lee JH, Mehnert JA, Yudd A, et al. A phase 0 trial of Riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res. 2009;15(11):3896\u2013902.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"732_CR13","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/pcmr.12694","volume":"31","author":"JM Mehnert","year":"2018","unstructured":"Mehnert JM, Silk AW, Lee JH, Dudek L, Jeong BS, Li J, et al. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma. Pigment Cell Melanoma Res. 2018;31(4):534\u201340.","journal-title":"Pigment Cell Melanoma Res"},{"key":"732_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/1479-5876-9-204","volume":"9","author":"O Hamid","year":"2011","unstructured":"Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204.","journal-title":"J Transl Med"},{"issue":"7528","key":"732_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"7","key":"732_CR16","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","volume":"28","author":"K Haratani","year":"2017","unstructured":"Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol. 2017;28(7):1532\u20139.","journal-title":"Ann Oncol"},{"key":"732_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.5_suppl.79","author":"AWSB Silk","year":"2020","unstructured":"Silk AW, Saraiay B, Groisberg R, Chan N, Spencer KR, Girda E, Shih W, Manne V, Palmeri M, Berman R, Coric V, Vieth J, Chen S, Mehnert JM, Malhorta J. A phase Ib study of troriluzole (BHV-4157) in combination with nivolumab. Clinical Immuno-Oncol Symposium. 2020. https:\/\/doi.org\/10.1200\/JCO.2020.38.5_suppl.79 (ASCO-SITC Abstract 79).","journal-title":"Clinical Immuno-Oncol Symposium"},{"key":"732_CR18","unstructured":"Rilutek [package insert]. Cary, North Carolina, USA: Covis Pharmaceuticals, Inc. 2016.\u00a0"},{"key":"732_CR19","doi-asserted-by":"publisher","DOI":"10.3171\/2021.1.JNS202482","author":"R Medikonda","year":"2021","unstructured":"Medikonda R, Choi J, Pant A, Saleh L, Routkevitch D, Tong L, et al. Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma. J Neurosurg. 2021. https:\/\/doi.org\/10.3171\/2021.1.JNS202482.","journal-title":"J Neurosurg"},{"issue":"6","key":"732_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/1740774510382799","volume":"7","author":"Y Ji","year":"2010","unstructured":"Ji Y, Liu P, Li Y, Bekele BN. A modified toxicity probability interval method for dose-finding trials. Clin Trials. 2010;7(6):653\u201363.","journal-title":"Clin Trials"},{"issue":"52","key":"732_CR21","doi-asserted-by":"publisher","first-page":"87037","DOI":"10.18632\/oncotarget.13523","volume":"7","author":"L Gao","year":"2016","unstructured":"Gao L, Wang F-Q, Li H-M, Yang J-G, Ren J-G, He K-F, et al. CCL2\/EGF positive feedback loop between cancer cells and macrophages promotes cell migration and invasion in head and neck squamous cell carcinoma. Oncotarget. 2016;7(52):87037\u201351.","journal-title":"Oncotarget"},{"issue":"11","key":"732_CR22","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1172\/JCI87252","volume":"126","author":"M Yin","year":"2016","unstructured":"Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016;126(11):4157\u201373.","journal-title":"J Clin Invest"},{"key":"732_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3958069","author":"M Fabbi","year":"2017","unstructured":"Fabbi M, Carbotti G, Ferrini S. Dual roles of IL-27 in cancer biology and immunotherapy. Mediators Inflamm. 2017. https:\/\/doi.org\/10.1155\/2017\/3958069.","journal-title":"Mediators Inflamm"},{"issue":"2","key":"732_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/cancers13020167","volume":"13","author":"B Mirlekar","year":"2021","unstructured":"Mirlekar B, Pylayeva-Gupta Y. IL-12 family cytokines in cancer and immunotherapy. Cancers (Basel). 2021;13(2):167.","journal-title":"Cancers (Basel)"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00732-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00732-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00732-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T04:10:20Z","timestamp":1656735020000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00732-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00732-w","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Rutgers University Institutional Review Board, protocol #051707. All subjects signed written consent to participate. All procedures were carried out in accordance to institutional guidelines and regulations for clinical trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients gave written consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AWS has received research funding from Biohaven Pharmaceuticals to the institution. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"107"}}